GDF-15

There are 545 papers on GDF-15 in aging research: 34 trials and 342 observational studies in people, 48 in animals, 29 in cells, 85 reviews. The newest story, Nov 16, 2026: “Blood protein model better predicts future diabetes risk”.

Biomarker

545 papers study it13 more mention it570 findings

HGNCNCBI GeneTaxon

38 new papers in 30 daysSee all 558 papers on GDF-15

“Higher levels of GDF15 and TNFR1 were associated with a worse trajectory in the cognitive composite score in adjusted models.”
Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT studyGeroScience2025doi:10.1007/s11357-024-01497-2
  • Human trial34
  • Humans342
  • Animals48
  • Cells29
  • In silico4

Interventions

51

Metformin

upin mice2upin humans1upin mouse cells1upin rats1+95%

5 studies
  1. Metformin increases GDF-15 in humans (+95%).

    “Similarly, plasma GDF-15 concentrations were 95% higher in the M+ than in the M– examination (Fig. 1C) and plasma glucagon levels were 26% higher (Fig. 1D), while serum cortisol levels and plasma lipids were similar between both conditions (Table 2).”

    Human trial≥ 2 weeksmalesn = 16

    Metformin Lowers Fasting Hyperglycemia by Increasing Glucose Clearance in People with Moderately Controlled Type 2 Diabetes

    Drugs

  2. Metformin increases GDF-15 in humans (moderately controlled type 2 diabetes).

    “Metformin decreased hepatic ATP content by 16% and increased plasma GDF-15 concentrations”

    Human trialmoderately controlled type 2 diabetes1 g twice dailymalesn = 16

    Metformin Lowers Fasting Hyperglycemia by Increasing Glucose Clearance in People with Moderately Controlled Type 2 Diabetes

    Drugs

  3. Metformin increases GDF-15 in high-fat diet-fed wild-type mice.

    “metformin treatment ameliorated glucose intolerance and increased hepatic and circulating GDF15 levels in WT mice, but not in Ppard-/- mice fed a HFD”

    Animalsin high-fat diet-fed wild-type micei.g.plasma-serum200 mg ·kg−1 ·d−13 weeksmales

    PPARβ/δ contributes to the antidiabetic effect and the increase in GDF15 caused by metformin

    Acta pharmacologica Sinica

  4. Metformin increases GDF-15 in rats (streptozotocin-induced diabetes).

    “enhanced Klotho and GDF-15 expression”

    Animalsstreptozotocin-induced diabetes200 mg/kg/daymales

    Metformin-mediated protection against Immunosenescence in diabetic cardiomyopathy: The potential roles of GDF-15 and klotho proteins

    International immunopharmacology

  5. Metformin increases GDF-15 in mice (iMSUD mice).

    “Treatment with metformin was correlated with increased serum-levels of growth/differentiation factor GDF15 (GFD15) and adiponectin”

    AnimalsiMSUD mice

    Metformin extends the lifespan of iMSUD mice by rescuing physiologic dysfunction and modulating mechanisms of mTORC1 activation

    Preprint

  6. Metformin increases GDF-15 in mouse cells.

    “metformin induces expression and secretion of growth differentiating factor 15 (GDF15)”

    Cellshepatocytes

    Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

    Nature metabolism

More on Metformin

High-intensity functional training

downin humans3

3 studies
  1. High-intensity functional training decreases GDF-15 in men with metabolic syndrome.

    “A significant difference was found between the two groups for FGF-21 [F(1, 21) = 97.54, P < 0.001, η2 = 0.852] and GDF-15 [F(1, 21) = 93.09, P < 0.001, η2 = 0.846].”

    Human trialin men with metabolic syndrome12 weeksn = 24

    High-intensity functional training linked to lower markers in 12 men

    BMC sports science, medicine & rehabilitation

  2. High-intensity functional training decreases GDF-15 in humans (metabolic syndrome) (P = 0.001).

    “After the intervention, the FGF21 and GDF15 levels significantly decreased in the HIFT group (P = 0.001).”

    Human trialmetabolic syndromeserum12 weeksmalesn = 24

    The Effect of 12 Weeks of High Intensity Functional Training (HIFT) on Serum Mitokine and Metabolic Risk Factors in Patients with Metabolic Syndrome: A Randomized Control Trial

    Research SquarePreprint

  3. High-intensity functional training decreases GDF-15 in humans (training groups compared with the control group in men with obesity).

    “reductions of GDF15 levels in both training groups (p < 0.05)”

    Human trialtraining groups compared with the control group in men with obesity12 weeksmalesn = 68

    Astaxanthin Supplemented with High-Intensity Functional Training Decreases Adipokines Levels and Cardiovascular Risk Factors in Men with Obesity

    Nutrients

More on High-intensity functional training

Dasatinib + quercetin

upin human cells2

2 studies
  1. Dasatinib + quercetin increases GDF-15 in human cells (senescent normal and IPF fibroblasts).

    “D + Q augmented growth differentiation factor 15 (GDF15) transcript and protein levels in both normal and IPF senescent fibroblasts”

    Cellssenescent normal and IPF fibroblasts

    Standard of care drugs do not modulate activity of senescent primary human lung fibroblasts

    Scientific reports

  2. Dasatinib + quercetin increases GDF-15 in human cells (senescent normal and IPF fibroblasts).

    “D+Q enhanced growth differentiation factor 15 (GDF15) transcript and protein levels in both normal and IPF senescent fibroblasts.”

    Cellssenescent normal and IPF fibroblastslung fibroblast

    Effects of anti-fibrotic standard of care drugs on senescent human lung fibroblasts

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

More on Dasatinib + quercetin

Exercise

no changein dogs1upin reviews1

2 studies
  1. Exercise showed no clear effect on GDF-15 in dogs across racing time points and in older cohort (approx 350 pg/mL).

    “GDF-15 median serum concentrations did not change significantly across any racing time point (approx 350 pg/mL) or in the older cohort.”

    Animalsacross racing time points and in older cohort

    Serum myostatin decreases in exercising and aging Alaskan sled dogs, while growth and differentiation factor 15 remains unaltered

    Journal of the American Veterinary Medical Association

  2. Exercise induces GDF-15 in skeletal muscle under intense exercise.

    “GDF15 expression and secretion can be induced in various stress conditions, such as intense exercise and acute myocardial infarction”

    Reviewin skeletal muscle under intense exerciseskeletal muscle

    The Role of GDF15 as a Myomitokine

    Cells

More on Exercise

Combined aerobic and resistance training

upin humans1

1 study
  1. Combined aerobic and resistance training increases GDF-15 in humans (group × time interaction across obesity groups) (group × time interaction p < 0.05; main group effect p < 0.05).

    “led to increased GDF-15, indicating potential metabolic benefits”

    Human trialgroup × time interaction across obesity groups16 weeksfemales

    The Effects of a Combined Exercise Intervention on Body Composition, GDF-15, Apelin-12, and IL-15 Among Older Korean Women According to Obesity Status

    Journal of clinical medicine

  2. Combined aerobic and resistance training increases GDF-15 in humans.

    “An interaction effect between group and time was observed (p < 0.05), and a main effect between the groups was found (p < 0.05).”

    Human trial16 weeksfemalesn = 29

    The Effects of a Combined Exercise Intervention on Body Composition, GDF-15, Apelin-12, and IL-15 Among Older Korean Women According to Obesity Status

    Journal of clinical medicine

More on Combined aerobic and resistance training

Conjugated equine estrogens

downin humans1

1 study
  1. Conjugated equine estrogens decrease GDF-15 in humans (compared with placebo) (-108 pg/mL (p = .008)).

    “Serum levels of GDF15, TNFR1, and FAS, but not MIP1α, were lower in both the oCEE and tE2 groups compared to placebo.”

    Human trialcompared with placebooral36 monthsfemalesn = 37

    Effect of menopausal hormone therapy on proteins associated with senescence and inflammation

    Physiological reports

  2. Conjugated equine estrogens decrease GDF-15 in humans (−108 pg/ml (95% CI −180, −31)).

    “GDF15, TNFRI, and FAS level difference estimates (95% CI) were −108 (−180, −31), −234 (−348, −120), and −1374 (−1940, −711) pg/ml respectively (all adjusted p‐values < 0.02) for the oCEE versus placebo groups.”

    Human trial48 months

    Effect of menopausal hormone therapy on proteins associated with senescence and inflammation

    Physiological reports

More on Conjugated equine estrogens

Total sleep time

no changein humans1

1 study
  1. Total sleep time was not clearly linked with GDF-15 in humans after multivariable adjustment.

    “TST and PiB-PET global SUVR were not significantly associated with GDF-15”

    Humansafter multivariable adjustmentn = 118

    Association of plasma growth differentiation factor 15 with wake after sleep onset in mild cognitive impairment

    The journal of nutrition, health & aging

More on Total sleep time

Lifestyle modification program

no changein humans1

1 study
  1. Lifestyle modification program showed no clear effect on GDF-15 in humans (changes appeared time-dependent rather than intervention-specific).

    “Neither GDF-15 nor SOST demonstrated a significant intervention-specific effect.”

    Human trialchanges appeared time-dependent rather than intervention-specific6 monthsn = 181

    Lifestyle modification reduces phenotypic age in adults with prediabetes

    Frontiers in aging

More on Lifestyle modification program

Lifestyle modification

no changein humans1

1 study
  1. Lifestyle modification showed no clear effect on GDF-15 in humans.

    “Both groups showed reductions in GDF15, but the intervention did not produce a statistically significant difference ( Table 3 ).”

    Human trial6-monthn = 181

    Lifestyle modification reduces phenotypic age in adults with prediabetes

    Frontiers in aging

More on Lifestyle modification

Time-restricted feeding

upin human cells1

1 study
  1. Time-restricted feeding increases GDF-15 in human cells (serum transfer to human cerebromicrovascular endothelial cells).

    “These changes were accompanied by marked induction of the stress-responsive cytokine GDF15.”

    Cellsserum transfer to human cerebromicrovascular endothelial cellsserum from aged individuals practicing TREcerebromicrovascular endothelial cells

    Circulating factors induced by time-restricted eating drive metabolic reprogramming in endothelial cells

    GeroScience

More on Time-restricted feeding

Empagliflozin

downin humans1

1 study
  1. Empagliflozin decreases GDF-15 in humans (7-fold).

    “GDF-15 expression was also reduced (7-fold) in the intervention group 0.198 ± 0.22 compared to placebo group 1.66 ± 1.04 (P ˂ 0.0001).”

    Human trialtablets12 weeks

    Impact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial

    Journal of cardiovascular and thoracic research

More on Empagliflozin

Nucleotides

downin humans1

1 study
  1. Nucleotides decrease GDF-15 in the Low-PRS group (β = −105.72, 95% CI −179.01 to −32.42).

    “NTs supplementation also resulted in reductions of circulating GDF15 (β = −105.72, 95% CI −179.01 to −32.42, p = 0.0047) and IL‐1β (β = −92.27, 95% CI −177.71 to −6.84, p = 0.034).”

    Human trialin the Low-PRS group19 weeks

    Urate-Related Genetic Risk Modulates the Anti-Aging Effects of Exogenous Nucleotides: Multi-Omics Evidence From Older Adults

    Aging cell

More on Nucleotides

Exenatide

upin humans1

1 study
  1. Exenatide increases GDF-15 in humans (16 weeks of add-on treatment) (721.9 (513.6, 997.8) to 741.4 (510.0, 1203.4) pg/mL, p = 0.031).

    “GDF15 levels were significantly increased from baseline following 16 weeks of exenatide treatment”

    Human trial16 weeks of add-on treatment16 weeksn = 166

    Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial

    Biomedicines

More on Exenatide

Acute social-evaluative stress

upin humans1

1 study
  1. Acute social-evaluative stress increases GDF-15 in humans.

    “acute social-evaluative stress significant increased GDF15 levels in plasma and saliva within minutes”

    Human trialplasma and saliva

    The energetic stress cytokine GDF15 is elevated in the context of chronic and acute psychosocial stress

    bioRxiv : the preprint server for biologyPreprint

More on Acute social-evaluative stress

Multi-component nutritional supplement

no changein humans1

1 study
  1. Multi-component nutritional supplement showed no clear effect on GDF-15 in humans.

    “No significant effect of the supplement was observed for GDF-15, a marker linked to aging.”

    Human trial12 weeksn = 83

    A combination nutritional supplement reduces DNA methylation age only in older adults with a raised epigenetic age

    GeroScience

More on Multi-component nutritional supplement

All 51

Effects

94

Cellular senescence

upin human cells2mediatesin human cells1downin human cells1

4 studies
  1. GDF-15 mediates cellular senescence in human cells (shown by simultaneous PLIN2 and GDF15 knockdown).

    “the simultaneous KD of PLIN2 and GDF15 abrogated the induction of cell senescence, suggesting that the increase in GDF15 is the mediator”

    Cellsshown by simultaneous PLIN2 and GDF15 knockdown

    Downregulation of PLIN2 in human dermal fibroblasts impairs mitochondrial function in an age-dependent fashion and induces cell senescence via GDF15

    Aging cell

  2. GDF-15 decreases cellular senescence in human cells (shown by knockdown in human dermal fibroblasts).

    “knocking down GDF15 expression in human dermal fibroblasts induced mitochondrial dysfunction and premature senescence”

    Cellsshown by knockdown in human dermal fibroblasts

    Depletion of growth differentiation factor 15 (GDF15) leads to mitochondrial dysfunction and premature senescence in human dermal fibroblasts

    Aging cell

  3. GDF-15 increases cellular senescence in human cells (shown by CRISPR/Cas9 knockout in CS extract-treated cells).

    “Disruption of GDF15 significantly inhibited CS extract-induced airway epithelial senescence.”

    Cellsshown by CRISPR/Cas9 knockout in CS extract-treated cellsairway epithelial cells

    Cigarette Smoke Induces Human Airway Epithelial Senescence via Growth Differentiation Factor 15 Production

    American journal of respiratory cell and molecular biology

  4. GDF-15 increases cellular senescence in human cells (ionizing radiation exposure; shown by GDF15 downregulation).

    “downregulation of GDF15 in HAECs partially prevented cellular senescence triggered by IR”

    Cellsionizing radiation exposure; shown by GDF15 downregulationhuman aortic endothelial cells

    GDF15 contributes to radiation-induced senescence through the ROS-mediated p16 pathway in human endothelial cells

    Oncotarget

More on Cellular senescence

Atrial fibrillation

mediatesin humans2

2 studies
  1. GDF-15 is linked with atrial fibrillation in humans (mediating the association of air pollution with AF risk).

    “Mediation analysis identified specific pathogenic axes, highlighting ANGPT2, GDF15, and PLAUR as candidate molecular transducers linking pollution to AF risk.”

    Humansmediating the association of air pollution with AF risk

    Air pollution-related proteomic signatures, molecular mediators, and AF-free life loss: A large-scale proteome-wide analysis

    Ecotoxicology and environmental safety

  2. GDF-15 is linked with atrial fibrillation in humans (one of 18 proteins partially mediating the LE8–AF association).

    “Mediation analyses identified 18 proteins (e.g., GDF15 and CLMP) that partially mediated the association between LE8 and AF.”

    Humansone of 18 proteins partially mediating the LE8–AF association

    Proteomic signatures of life's essential 8 and incident atrial fibrillation among individuals with chronic kidney disease

    Nutrition & metabolism

More on Atrial fibrillation

Cognitive decline

no changein humans2

2 studies
  1. GDF-15 was not clearly linked with cognitive decline in humans (direct effect, after accounting for physical frailty) (β = 0.100 (95% CI: -0.991 to 1.190)).

    “whereas the direct effect was not significant (β = 0.100, 95% CI: -0.991 to 1.190)”

    Humansdirect effect, after accounting for physical frailtyn = 134

    Association of Physical Frailty With Serum Growth Differentiation Factor-15 and Cognitive Decline: A Cross-Sectional Study

    Geriatrics & gerontology international

  2. GDF-15 was not clearly linked with cognitive decline in humans (over follow-up, 11 cognitive test scores).

    “GDF15 was not associated with decline on any of the 11 cognitive test scores considered in ∼ 4 years of follow-up.”

    Humansover follow-up, 11 cognitive test scoresserum~4 years

    GDF15 and its association with cognitive performance over time in a longitudinal study of middle-aged urban adults

    Brain, behavior, and immunity

All-cause dementia

mediatesin humans2

2 studies
  1. GDF-15 is linked with all-cause dementia in humans (Mediation of the relationship between physical activity and incident all-cause dementia) (21 unique proteins identified as mediators).

    “GDF15, ITGAV, ITGAM, ITGA11, HPGDS, GFAP, ADM, AHNAK, and DPP4 were among 21 unique proteins found to mediate the relationship of PA with all-cause dementia”

    HumansMediation of the relationship between physical activity and incident all-cause dementiaplasma

    Plasma Proteomic Signatures of Physical Activity Provide Insights into Biological Impacts and its Protective Role against Dementia

    Medicine and science in sports and exercise

  2. GDF-15 is linked with all-cause dementia in humans (mediating the association between degenerative joint diseases and all-cause dementia) (mediation proportion 22%, 95% CI 14.5–46.8%).

    “Mediation analysis revealed that 18 proteins, including HAVCR1 (mediation proportion 52.6 %, 95 % CI: 39.1 %-78 %), GDF15 (22 %, 95 % CI: 14.5 %-46.8 %)”

    Humansmediating the association between degenerative joint diseases and all-cause dementia

    Plasma proteomics mediate the association between degenerative joint diseases and dementia risk

    Journal of advanced research

More on All-cause dementia

Exercise tolerance

downin mice2

2 studies
  1. GDF-15 impairs exercise tolerance in mice (cardiomyocyte knockdown in PGC-1α-deficient mice).

    “Cardiomyocyte-specific reduction of GDF15 preserves exercise tolerance, cardiac function, and exercise-induced cardiomyocyte hypertrophy in PGC-1α-deficient mice.”

    Animalscardiomyocyte knockdown in PGC-1α-deficient miceheart

    Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α

    AHA Scientific Sessions 2025 abstract

  2. GDF-15 impairs exercise tolerance in mice.

    “Cardiomyocyte-specific reduction of GDF15 expression preserves exercise tolerance and cardiac contractility in PGC-1α-deficient mice during endurance training.”

    Animalsshown by cardiomyocyte-specific knockdown in PGC-1α-deficient mice during endurance trainingheart

    Cardiomyocyte PGC-1α enables physiological adaptations to endurance exercise through suppression of GDF15 and cardiac atrophy

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

Appendicular lean mass

downin humans1no changein humans1OR 0.984

2 studies
  1. GDF-15 is linked with lower appendicular lean mass in humans (Mendelian randomization using genetic instruments) (OR = 0.984, 95% CI = 0.974-0.993, pIVW = 7.658E-04).

    “GDF-15 was negatively correlated with all four traits of sarcopenia”

    HumansMendelian randomization using genetic instruments

    Role of CD127 on CD28⁺ CD45RA⁺ CD8br Treg Cells in Mediating the Association Between GDF-15 and Sarcopenia

    Rejuvenation research

  2. GDF-15 was not clearly linked with appendicular lean mass in humans (fully adjusted longitudinal models).

    “ALM, β=2.1E-05;95%CI=-2.6E-04,3.03E-04;p>0.05”

    Humansfully adjusted longitudinal models2 yearsn = 168

    Circulating Levels of Apelin, GDF-15 and Sarcopenia: Lack of Association in the MAPT Study

    The journal of nutrition, health & aging

Dementia

mediatesin humans2

2 studies
  1. GDF-15 is linked with dementia in humans (POHP-dementia association, as pure indirect effect) (explains 28% of the total effect of POHP on dementia).

    “Growth differentiation factor 15 (GDF15) exhibited the strongest mediating effects (PIE > 0, P < 0.001), explaining 28% the total effect of POHP on dementia, as a pure indirect effect.”

    HumansPOHP-dementia association, as pure indirect effectup to 15 years of follow-upn = 37,269

    Mediating and moderating effects of plasma proteomic biomarkers on the association between poor oral health problems and incident dementia: The UK Biobank study

    GeroScience

  2. GDF-15 is linked with dementia in the association of hospital-treated infection with dementia.

    “The association of hospital-treated infections with dementia was partially mediated through GDF15 and other plasma proteomic markers.”

    Humansin the association of hospital-treated infection with dementia

    Hospital-treated prevalent infections, the plasma proteome and incident dementia among UK older adults

    iScience

More on Dementia

Sarcopenia

no changein humans2OR 1.001

2 studies
  1. GDF-15 was not clearly linked with sarcopenia in humans (fully adjusted longitudinal models) (OR=1.001 (95%CI 1.000, 1.002)).

    “plasma GDF-15 was not associated with both the incidence of sarcopenia (OR=1.001,95%CI=1.000,1.002,p>0.05)”

    Humansfully adjusted longitudinal models2 yearsn = 168

    Circulating Levels of Apelin, GDF-15 and Sarcopenia: Lack of Association in the MAPT Study

    The journal of nutrition, health & aging

  2. GDF-15 was not clearly linked with sarcopenia in humans.

    “Serum GDF15 levels were not significantly different according to sarcopenia status”

    Humansn = 125

    Serum GDF15 Level Is Independent of Sarcopenia in Older Asian Adults

    Gerontology

More on Sarcopenia

Lifespan

upin mice2

2 studies
  1. GDF-15 extends lifespan in mice (overexpression).

    “GDF15, for example, extends both lifespan and healthspan when overexpressed in mice”

    Reviewoverexpression

    Systematic review and analysis of human proteomics aging studies unveils a novel proteomic aging clock and identifies key processes that change with age

    Ageing research reviews

  2. GDF-15 extends lifespan in mice.

    “female hNAG-1 mice had significantly increased both mean and median life spans in two transgenic lines”

    Animalstransgenic overexpression in two lines; larger difference on high-fat diet than low-fat dietfemales

    hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling

    Aging

Prediction of non-cardiovascular and cancer mortality

upin humans1

1 study
  1. GDF-15 is linked with better prediction of non-cardiovascular and cancer mortality in humans (Non-CV: cNRI 0.273, P=0.030; IDI 0.017, P=0.005. Cancer: cNRI 0.231, P=0.016; IDI 0.004, P=0.029).

    “significantly improved the prediction of non-CV and cancer deaths in the entire cohort”

    HumansAddition to a model containing clinical confounders and established cardiovascular biomarkers in the entire cohortserum6 yearsn = 1,281

    Impact of Chronic Kidney Disease on the Predictive Value of Growth Differentiation Factor 15 for Cause-Specific Mortality in Patients with Diabetes and Coronary Artery Disease: The EXCEED-J Study

    AHA Scientific Sessions 2026 abstract

HbA1c reduction

no changein humans1

1 study
  1. GDF-15 showed no clear effect on HbA1c reduction in humans after adjusting for age and diabetes duration.

    “no significant relationship was found between GDF15 (tertile 2: p = 0.403; tertile 3: p = 0.217) and ΔHbA1c after adjusting for age and diabetes duration”

    Human trialafter adjusting for age and diabetes duration16 weeksn = 166

    Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial

    Biomedicines

More on HbA1c reduction

Energy intake

no changein humans1

1 study
  1. GDF-15 showed no clear effect on energy intake in humans during intermittent fasting and caloric restriction.

    “but not associated with energy intake”

    Human trialduring intermittent fasting and caloric restriction8 weeksfemales

    Intermittent fasting increases growth differentiation factor 15 in females with overweight or obesity but not associated with food intake

    Obesity research & clinical practice

Body weight

no changein humans1

1 study
  1. GDF-15 showed no clear effect on body weight in humans (change in plasma GDF15 with exercise training).

    “ΔGDF15 was not correlated with change in weight, BMI, or resting energy expenditure.”

    Human trialchange in plasma GDF15 with exercise training12 weeksn = 24

    Exercise training promotes a GDF15-associated reduction in fat mass in older adults with obesity

    American journal of physiology. Endocrinology and metabolism

All 94

Upstream

22

Age

upin humans3upin mice1+33% over five years

4 studies
  1. Age is linked with higher GDF-15 in humans (longitudinal, two timepoints 5 years apart) (+33% over five years).

    “and increased by 33% over five years”

    Humanslongitudinal, two timepoints 5 years apart5 yearsn = 430

    Blood mitochondrial health markers cf-mtDNA and GDF15 in human aging

    bioRxiv : the preprint server for biologyPreprint

  2. Age is linked with higher GDF-15 in humans (1.1 ± 0.4 pg·mL−1 ·year−1 in women; 3.3 ± 0.6 pg·mL−1 ·year−1 in men).

    “Systemic levels of GDF15 increased progressively as a function of age in women (1.1 ± 0.4 pg·mL−1 ·year−1 ) and men (3.3 ± 0.6 pg·mL−1 ·year−1 ) (both P < 0.05).”

    Humans

    Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study

    Journal of cachexia, sarcopenia and muscle

  3. Age is linked with higher GDF-15 in humans (apparently healthy community-dwelling older adults).

    “Smoothed centile curves showed increasing GDF-15 with age in the apparently healthy participants.”

    Humansapparently healthy community-dwelling older adultsn = 268

    Growth differentiation factor 15 in a community-based sample: age-dependent reference limits and prognostic impact

    Upsala journal of medical sciences

  4. Age increases GDF-15 in mice.

    “GDF-15 levels in tissue and serum increased with age in these mice.”

    Animals

    Growth differentiation factor-15 as a biomarker for sarcopenia in aging humans and mice

    Experimental gerontology

Chronological age

upin humans1no changein humans1

2 studies
  1. chronological age is linked with higher GDF-15 in humans across pediatric, adult and geriatric samples.

    “Across all age groups, 25 protein-coding genes showed progressive expression shifts with aging, including upregulation of CLDN2, MUC2, and GDF15”

    Humansacross pediatric, adult and geriatric samplesvermiform appendix

    Age-Related Transcriptomic Changes in the Vermiform Appendix

    International journal of molecular sciences

  2. Chronological age was not clearly linked with GDF-15 in humans (multivariate linear regression on lnGDF-15 in acute coronary syndrome patients).

    “while age was not significant (p = 0.17)”

    Humansmultivariate linear regression on lnGDF-15 in acute coronary syndrome patientsn = 208

    Growth differentiation factor 15 and geriatric conditions in acute coronary syndrome

    International journal of cardiology

Celiac disease

upin humans1

1 study
  1. Celiac disease is linked with higher GDF-15 in humans.

    “Of note, GDF-15, a marker of general poor health(7) and unfavourable outcome in CVD(8), was higher in individuals with CeD (p=.049; see figure).”

    Humans

    Traditional risk factors underestimate cardiovascular risk in individuals with coeliac disease in the Trondelag Health Study (HUNT4)

    ESC Congress 2026 abstract

More on Celiac disease

PiB-PET global SUVR

no changein humans1

1 study
  1. PiB-PET global SUVR was not clearly linked with GDF-15 in humans after multivariable adjustment.

    “TST and PiB-PET global SUVR were not significantly associated with GDF-15”

    Humansafter multivariable adjustmentn = 118

    Association of plasma growth differentiation factor 15 with wake after sleep onset in mild cognitive impairment

    The journal of nutrition, health & aging

More on PiB-PET global SUVR

End-stage liver disease

upin humans1

1 study
  1. End-stage liver disease is linked with higher GDF-15 in humans (stratified by aetiology (alcohol-related, NAFLD, viral hepatitis, other)) (p < 0.0001).

    “with only GDF-15 significantly (p < 0.0001) elevated in all groups”

    Humansstratified by aetiology (alcohol-related, NAFLD, viral hepatitis, other)

    Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease

    Journal of cachexia, sarcopenia and muscle

More on End-stage liver disease

MFN2

downin mice1

1 study
  1. MFN2 decreases GDF-15 in mice (shown by endothelial-specific deletion).

    “Mfn2iΔEC mice exhibited elevated endothelial and circulating GDF15 levels”

    Animalsshown by endothelial-specific deletionendothelial cells

    Deletion of Mfn2 in endothelial cells triggers a mitohormetic response that improves systemic metabolism and healthspan in mice

    Cell metabolism

More on MFN2

CD4+ nadir

no changein humans1

1 study
  1. CD4+ nadir was not clearly linked with GDF-15 in humans.

    “CD4+ nadir showed no significant association with GDF-15.”

    Humans

    Elevated Plasma GDF-15 Levels Are Associated with Aging, Multimorbidity, and Tobacco Exposure in People with HIV

    Infectious diseases and therapy

More on CD4+ nadir

Age-multimorbidity ordinal category

upin humans1+16% increase per category

1 study
  1. age-multimorbidity ordinal category is linked with higher GDF-15 in humans (16.0% increase per category).

    “In the hospital cohort, smoking and age-multimorbidity were independently associated with elevated GDF-15, with 26.1% and 16.0% increases per category, respectively (p < 0.05).”

    Humanshospital cohort; multivariable linear regression adjusted for tobacco smoking and CD4+ nadir

    Elevated Plasma GDF-15 Levels Are Associated with Aging, Multimorbidity, and Tobacco Exposure in People with HIV

    Infectious diseases and therapy

PPARGC1A

downin mice1

1 study
  1. PPARGC1A decreases GDF-15 in mice (shown by cardiomyocyte knockout, in trained hearts).

    “markedly increased expression of the myomitokine GDF15”

    Animalsshown by cardiomyocyte knockout, in trained heartsheart5 weeks

    Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α

    AHA Scientific Sessions 2025 abstract

More on PPARGC1A

TP53

upin human cells1

1 study
  1. TP53 activates GDF-15 in human cells (via both WT p53Ser392 and mutated p53N239Y).

    “its active gene transcription of GDF-15 via both WT p53Ser392 and Mutated p53N239Y transcription factors”

    Cellsvia both WT p53Ser392 and mutated p53N239Y

    The dark side of the light (UVA): melanoma microenvironment and cell survival strategies

    Cell death discovery

More on TP53

All 22

Associations

264

Mortality

upin humans23HR 1.32–2.47

23 studies
  1. GDF-15 predicts mortality in humans (Hospitalized patients; multivariable adjustment) (HR 1.32, 95% CI 1.17–1.49).

    “Higher GDF-15 and sST2 levels independently predicted mortality after multivariable adjustment”

    HumansHospitalized patients; multivariable adjustmentMedian follow-up of 4.2 yearsn = 966

    GDF-15 and sST2 as independent predictors of long-term mortality in hospitalized older adults: a prospective cohort study

    Mechanisms of ageing and development

  2. GDF-15 is associated with mortality in humans (Adjusted HR 1.40, 95% CI 1.17–1.69 per 1-SD increase in log-transformed GDF-15).

    “were significantly associated with all-cause (adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.17-1.69)”

    HumansDiabetes and suspected or known coronary artery disease; adjusted association per 1-SD increase in log-transformed GDF-15serum6 yearsn = 1,281

    Impact of Chronic Kidney Disease on the Predictive Value of Growth Differentiation Factor 15 for Cause-Specific Mortality in Patients with Diabetes and Coronary Artery Disease: The EXCEED-J Study

    AHA Scientific Sessions 2026 abstract

  3. GDF-15 is associated with mortality in humans.

    “macrophage inhibitory cytokine 1 (MIC-1) (growth differentiation factor 15 (GDF15)), human epididymis protein 4 (HE4), and insulin-like growth factor-binding protein 2 (IGFBP-2) were associated with increased mortality”

    Humansplasma

    Blood proteins linked to death risk in older adults

    Geromedicine

  4. GDF-15 is linked with a higher risk of mortality in humans (per SD, plasma proteomics) (HRperSD 1.56 (95% CI 1.42-1.72)).

    “GDF15 (HRperSD [95% CI] = 1.56 [1.42-1.72]), WFDC2 (1.47 [1.33-1.62]) and TIMP1 (1.45 [1.29-1.62]) were the leading proteomic candidates associated with mortality.”

    Humansper SD, plasma proteomics16 yearsn = 861

    Proteomic organ clocks predict mortality but trail established physiological and epigenetic biomarkers

    Aging cell

  5. GDF-15 predicts mortality in humans (elevated plasma levels (>1081 pg/mL)) (HR 2.47, 95% CI: 1.19-5.13).

    “Elevated GDF15 independently predicted all-cause mortality (HR 2.47, 95% CI: 1.19-5.13)”

    Humanselevated plasma levels (>1081 pg/mL)median follow-up of 6.2 yearsn = 1,532

    Growth Differentiation Factor 15 as a Biomarker of Cardiovascular Burden and Mortality in a Population-Based Cohort

    International journal of molecular sciences

  6. GDF-15 predicts mortality in humans after acute coronary syndrome (time-dependent AUC 0.82 [95% CI 0.75–0.89] vs. 0.76 [95% CI 0.67–0.84]; P = 0.001).

    “GDF-15 outperformed GRACE 2.0 for 3-year mortality prediction (time-dependent AUC 0.82 [95% CI 0.75–0.89] vs. 0.76 [95% CI 0.67–0.84]; P = 0.001).”

    Humansafter acute coronary syndrome3 yearsn = 751

    Growth differentiation factor-15 improves long-term mortality risk prediction beyond the GRACE 2.0 score after acute coronary syndrome

    Scientific reports

  7. GDF-15 is associated with mortality in humans (normoglycemia and prediabetes).

    “Three proteins (GDF15, EDA2R, and WFDC2) were shared across all groups, with GDF15 emerging as the top-ranked important protein in normoglycemia and prediabetes”

    Humansnormoglycemia and prediabetes

    Glycemic status-dependent proteomic signatures of biological aging for health risk prediction

    GeroScience

  8. GDF-15 is linked with a higher risk of mortality in humans (HR 2.35 (95% CI 1.63-3.41), p<0.0001).

    “GDF-15 showed a stronger association with mortality, whereas eGFRdiff was more strongly linked to CKD progression.”

    Humansin individuals with diabetes mellitus; adjusted for age, sex, glycated haemoglobin, UACR and eGFRcrmedian follow-up 5.4 yearsn = 638

    Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF-15 With Adverse Outcomes in Diabetes Mellitus

    Journal of cachexia, sarcopenia and muscle

  9. GDF-15 predicts mortality in humans among prefrail and frail individuals.

    “GDF15, WFDC2, and NEFL were the most important proteins predicting death among prefrail and frail individuals.”

    Humansamong prefrail and frail individuals

    Plasma proteomic signature of risk and prognosis of frailty in the UK Biobank

    GeroScience

  10. GDF-15 is linked with a higher risk of mortality in humans (highest vs lowest quartile of GDF-15).

    “and mortality (HR: 1.81 [1.53, 2.15])”

    Humanshighest vs lowest quartile of GDF-15

    Associations of Serum GDF-15 Levels with Physical Performance, Mobility Disability, Cognition, Cardiovascular Disease, and Mortality in Older Adults

    medRxiv : the preprint server for health sciencesPreprint

All 23

Age

upin humans12mixedin humans1

13 studies
  1. GDF-15 is associated with age in humans (rho 0.617).

    “showed a strong positive association with aging (rho 0.617, p < 0.001)”

    Humansn = 4,842

    Growth Differentiation Factor 15 and Physical Function Impairment in the SardiNIA Study

    Journal of clinical medicine

  2. GDF-15 predicts age in humans (transcript levels across 40 human tissues).

    “GDF15 and EDA2R, which demonstrated strong predictive power for aging”

    Humanstranscript levels across 40 human tissues

    Global and tissue-specific transcriptomic dysregulation in human aging: Pathways and predictive biomarkers

    GeroScience

  3. GDF-15 is associated with age in humans.

    “Non-linear relationships were also identified with age for IGFBP-1, leptin, β2M, TNFRSF1B, fibrinogen, GDF-15, N-cadherin, and BDNF.”

    Humansnon-linear age trajectory; same finding for IGFBP-1, leptin, β2M, TNFRSF1B, fibrinogen, N-cadherin and BDNF6 years

    Longitudinal changes in blood-borne geroscience biomarkers: results from a population-based study

    GeroScience

  4. GDF-15 is associated with age in humans.

    “In correlation analysis, GDF15 was positively correlated with age”

    Humans

    Serum Growth Differentiation Factor 15 is Negatively Associated with Leukocyte Telomere Length

    The journal of nutrition, health & aging

  5. GDF-15 is associated with age in humans (r=0.66).

    “GDF15 showed a positive, exponential association with age (r=0.66, p<0.0001)”

    Humansn = 430

    Blood mitochondrial health markers cf-mtDNA and GDF15 in human aging

    bioRxiv : the preprint server for biologyPreprint

  6. Age is associated with GDF-15 in humans (particularly in individuals over 60).

    “GDF-15 levels significantly increase with age, particularly in individuals over 60.”

    Humansparticularly in individuals over 60n = 72

    GDF-15 as a proxy for epigenetic aging: associations with biological age markers, and physical function

    Biogerontology

  7. GDF-15 is associated with age in people living with HIV and healthy subjects.

    “GDF-15 levels were positively correlated with age”

    Humansin people living with HIV and healthy subjects

    Circulating GDF-15: a biomarker for metabolic dysregulation and aging in people living with HIV

    Frontiers in aging

  8. GDF-15 is associated with age in humans (r = 0.664).

    “GDF15 positively correlated with age (r = 0.664, p < 0.001)”

    Humansmalesn = 120

    GDF15 as a biomarker of ageing

    Experimental gerontology

  9. GDF-15 is associated with age in humans (r=0.664).

    “GDF-15 positively correlated with age (r=0.664, p<0.001)”

    Humansmalesn = 120

    GDF-15 as a biomarker of aging

    Preprint

  10. GDF-15 is associated with age in humans (plasma from the Baltimore Longitudinal Study of Aging (BLSA) cohort).

    “Growth/differentiation factor 15 (GDF15), stanniocalcin 1 (STC1), and serine protease inhibitors (SERPINs), which significantly correlated with age in plasma from a human cohort”

    Humansplasma from the Baltimore Longitudinal Study of Aging (BLSA) cohortplasma

    A proteomic atlas of senescence-associated secretomes for aging biomarker development

    PLoS biology

All 13

Sarcopenia

upin humans11no changein humans1OR 1.96–2.35

11 studies
  1. GDF-15 is associated with sarcopenia in humans (adjusted multinomial logistic model; confirmed sarcopenia category) (aOR 1.9 (95% CI 1.3-2.6) for confirmed sarcopenia).

    “higher GDF-15 was associated with greater odds of probable (aOR = 1.6; 95% CI: 1.2-2.0) and confirmed sarcopenia (aOR = 1.9; 95% CI: 1.3-2.6)”

    Humansadjusted multinomial logistic model; confirmed sarcopenia categoryn = 2,347

    Association between GDF-15 and sarcopenia progression in older adults: results from a population-based study

    EBioMedicine

  2. GDF-15 is linked with a higher risk of sarcopenia in humans (particularly among individuals with low physical performance).

    “elevated serum levels of GDF15 and its receptor GFRAL are associated with an increased risk of sarcopenia, particularly among individuals with low physical performance”

    Humansparticularly among individuals with low physical performance

    Association between elevated expression of GDF15/GFRAL and sarcopenia risk

    iScience

  3. GDF-15 is associated with sarcopenia in humans (p = 0.03).

    “Elevated IL-6 and GDF-15 levels were significantly correlated with the presence of sarcopenia (p = 0.04 and p = 0.03, respectively)”

    Humansn = 179

    Interplay of IL-6, GDF-15 and Sarcopenia in Patients With Bladder Cancer Undergoing Radical Cystectomy and Its Implications on Survival

    Journal of cachexia, sarcopenia and muscle

  4. GDF-15 predicts sarcopenia in humans (AUC 0.577 (95% CI 0.501-0.653); diagnostic accuracy described as poor).

    “For sarcopenia, AUC was 0.577 (95% CI: 0.501-0.653).”

    Humansn = 429

    GDF-15 plasma levels are elevated in mobility-limited older adults with frailty and sarcopenia-results from the BIOFRAIL study

    GeroScience

  5. GDF-15 is associated with sarcopenia in humans (median 1916 vs 1569 pg/mL, p = 0.035).

    “Median GDF-15 levels in patients with/without sarcopenia and with/without frailty were 1916 pg/mL vs. 1569 pg/mL (p = 0.035), and 2252 pg/mL vs. 1438 pg/mL (p < 0.001), respectively.”

    Humansn = 429

    GDF-15 plasma levels are elevated in mobility-limited older adults with frailty and sarcopenia-results from the BIOFRAIL study

    GeroScience

  6. GDF-15 is associated with sarcopenia in humans (sarcopenic vs non-sarcopenic individuals) (r = 0.482).

    “The first meta-analysis, based on 4 studies (n = 1393), showed significantly higher levels of GDF-15 in sarcopenic individuals (r = 0.482).”

    Humanssarcopenic vs non-sarcopenic individualsn = 1,393

    The stress-responsive cytokine GDF-15 and sarcopenia: A systematic review and meta-analysis on aging muscle decline

    Mechanisms of ageing and development

  7. GDF-15 is associated with sarcopenia in humans (acutely admitted older medical patients) (P < 0.01).

    “Systemic GDF-15 was significantly higher in patients with either sarcopenia (P < 0.01) or frailty (P < 0.001) compared with patients without the conditions.”

    Humansacutely admitted older medical patientsn = 1,036

    GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients

    Journal of cachexia, sarcopenia and muscle

  8. GDF-15 predicts sarcopenia in humans (cutoff of 1109 pg/mL in subjects including patients receiving aortic valve replacement) (1109 pg/mL cutoff).

    “The GDF-15 concentration that defined sarcopenia was 1109 pg/mL in subjects including patients receiving aortic valve replacement.”

    Humanscutoff of 1109 pg/mL in subjects including patients receiving aortic valve replacement1109 pg/mLfemales

    Relationship between the serum GDF-15 concentration and muscle function in female patients receiving aortic valve replacement (TAVR, SAVR): Comparison with healthy elderly female subjects

    International journal of cardiology. Heart & vasculature

  9. GDF-15 is linked with a higher risk of sarcopenia in humans (GDF-15 level above 618.4 pg/mL cut-off) (OR 2.35; 95% CI 1.00-5.51).

    “the GDF-15 level was associated with a significantly greater likelihood of sarcopenia (odds ratio [OR] 2.35; 95% CI 1.00-5.51; p = 0.049)”

    HumansGDF-15 level above 618.4 pg/mL cut-offfemalesn = 146

    Associations Between Plasma Growth and Differentiation Factor-15 with Aging Phenotypes in Muscle, Adipose Tissue, and Bone

    Calcified tissue international

  10. GDF-15 is associated with sarcopenia in humans (highest vs lowest tertile, adjusted for cardiometabolic risk and biological factors) (OR 1.96 (95% CI 1.16-3.33)).

    “the highest GDF-15 tertile (≥1245 pg/mL) had an increased likelihood of sarcopenia (odds ratio, 1.96; 95% confidence interval, 1.16-3.33)”

    Humanshighest vs lowest tertile, adjusted for cardiometabolic risk and biological factorsn = 929

    Associations Between Elevated Growth Differentiation Factor-15 and Sarcopenia Among Community-dwelling Older Adults

    The journals of gerontology. Series A, Biological sciences and medical sciences

All 12

More on Sarcopenia

Frailty

upin humans10mixedin humans1HR 1.69

11 studies
  1. GDF-15 is associated with frailty in humans (GDF-15 measured at hospital discharge in COVID-19 survivors).

    “Of all the biomarkers tested, only GDF-15 at hospital discharge was associated with subsequent frailty.”

    HumansGDF-15 measured at hospital discharge in COVID-19 survivors3 yearsn = 150

    Frailty gap after COVID-19 lung injury narrowed over time

    CHEST critical care

  2. GDF-15 is linked with a higher risk of frailty in humans (very high versus lower plasma GDF-15, over 4-year follow-up) (HR 1.69 (95% CI 1.03-2.78)).

    “Longitudinally, very high GDF-15 levels predicted an increased risk of incident frailty (HR = 1.69, 95% CI = 1.03-2.78).”

    Humansvery high versus lower plasma GDF-15, over 4-year follow-up4-year follow-up

    Associations Between Growth Differentiating Factor-15 and Frailty in Older Adults From the MAPT Study

    Journal of cachexia, sarcopenia and muscle

  3. GDF-15 is associated with frailty in humans (cross-sectional comparison of high versus low plasma GDF-15) (OR 3.56 (95% CI 1.58-8.03), high vs low GDF-15).

    “Higher plasma GDF-15 levels (both as continuous and categorical) were cross-sectionally associated with frailty (high vs. low GDF-15: OR = 3.56, 95% CI = 1.58-8.03).”

    Humanscross-sectional comparison of high versus low plasma GDF-15

    Associations Between Growth Differentiating Factor-15 and Frailty in Older Adults From the MAPT Study

    Journal of cachexia, sarcopenia and muscle

  4. GDF-15 is associated with frailty in humans.

    “Other frailty-associated proteins were involved in tissue damage/repair (e.g., collagens, TFF3, GDF15)”

    Humansmalesn = 500

    Proteomic Associations and Signatures of Frailty Among Older Men

    GSA 2025 abstract

  5. GDF-15 is linked with a higher risk of frailty in humans (baseline levels) (AUC 0.85 (Fried Phenotype), 0.96 (Clinical Frailty Scale)).

    “Higher baseline GDF15 levels identified individuals at higher risk to become frail (AUC= 0.85 with Fried Phenotype and AUC= 0.96 with Clinical Frailty Scale)”

    Humansbaseline levelsplasma6-year follow-upn = 52

    Circulating mitokines GDF-15 and FGF21 are associated with frailty, sarcopenia, and malnutrition in older adults: Evidence from the FRASNET study

    Mechanisms of ageing and development

  6. GDF-15 predicts frailty in humans (OR 1.18 (95% CI 1.06–1.31) per 25% increment in GDF15).

    “1.24 (1.16-1.33) and 1.18 (1.06-1.31) for frailty.”

    HumansProspective analysis; per 25% increment in baseline GDF15, adjusted for potential confoundersserum2.2 yearsn = 2,481

    Growth differentiation factor 15 predicts physical function impairment in Spanish older adults: a real-world prospective study

    GeroScience

  7. GDF-15 is associated with frailty in humans (acutely admitted older medical patients) (P < 0.001).

    “Systemic GDF-15 was significantly higher in patients with either sarcopenia (P < 0.01) or frailty (P < 0.001) compared with patients without the conditions.”

    Humansacutely admitted older medical patientsn = 1,036

    GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients

    Journal of cachexia, sarcopenia and muscle

  8. GDF-15 is associated with frailty in humans (cross-sectional association with prevalent prefrailty and frailty) (p prefrailty = 1 × 10−15; p frailty = 2 × 10−19).

    “higher odds of prefrailty and frailty were observed with higher levels of growth differentiation factor 15”

    Humanscross-sectional association with prevalent prefrailty and frailtyn = 3,838

    Late-life plasma proteins associated with prevalent and incident frailty: A proteomic analysis

    Aging cell

  9. GDF-15 predicts frailty in humans (independent of LV mass, age, renal function and indices of LV dysfunction) (OR 1.05 (95% CI 0.9-1.1); p = 0.03).

    “GDF15 was significantly related to the Katz score, and predicted (OR 1.05; 95% CI 0.9-1.1; p = 0.03) a low (<5) Katz score”

    Humansindependent of LV mass, age, renal function and indices of LV dysfunction

    Growth Differentiation Factor 15 in Severe Aortic Valve Stenosis: Relationship with Left Ventricular Remodeling and Frailty

    Journal of clinical medicine

  10. Frailty is associated with GDF-15 in humans (multivariate linear regression on lnGDF-15 in acute coronary syndrome patients).

    “In multivariate analysis, frailty (Fried score, p = 0.001), and comorbidity (Charlson index, p = 0.003) were independent determinants of lnGDF-15”

    Humansmultivariate linear regression on lnGDF-15 in acute coronary syndrome patientsn = 208

    Growth differentiation factor 15 and geriatric conditions in acute coronary syndrome

    International journal of cardiology

All 12

Physical function

mixedin humans3downin humans2

5 studies
  1. GDF-15 is associated with physical function in humans (grip strength or gait speed).

    “Growth/differentiation factor 15, Insulin-like growth factor-binding protein 2, and Cystatin-C showed significant associations with inflammatory markers and measures of physical function (grip strength or gait speed).”

    Humansgrip strength or gait speed

    DIFFERENTIAL RESPONSES TO AGING AMONG THE TRANSCRIPTOME AND PROTEOME OF MESENCHYMAL PROGENITOR POPULATIONS

    GSA 2025 abstract

  2. GDF-15 is associated with physical function in humans.

    “negatively associated with physical performance and nutritional status after six years”

    Humansplasma6-year follow-upn = 52

    Circulating mitokines GDF-15 and FGF21 are associated with frailty, sarcopenia, and malnutrition in older adults: Evidence from the FRASNET study

    Mechanisms of ageing and development

  3. GDF-15 is associated with physical function in humans.

    “Growth/differentiation factor 15, Insulin-like growth factor-binding protein 2, and Cystatin-C showed significant associations with inflammatory markers and measures of physical function”

    Humans

    Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits

    The journals of gerontology. Series A, Biological sciences and medical sciences

  4. GDF-15 is associated with physical function in humans.

    “GDF-15 showed also a statistically significant correlation to gait speed, hand grip strength and walking duration.”

    Humansn = 1,470

    Association of growth differentiation factor 15 with other key biomarkers, functional parameters and mortality in community-dwelling older adults

    Age and ageing

  5. GDF-15 is associated with physical function in humans.

    “Elevated GDF-15 levels were consistently associated with poorer physical performance and greater frailty severity.”

    Review

    Growth differentiation factor-15 as a clinical biomarker of frailty, sarcopenia and functional decline: A systematic literature review

    Ageing research reviews

Muscle mass

downin humans4downin mice1

4 studies
  1. GDF-15 is associated with muscle mass in humans (r = -0.221).

    “The second meta-analysis, involving 4 studies (n = 1400), found a significant inverse correlation between GDF-15 and muscle mass (r = -0.221).”

    Humansskeletal musclen = 1,400

    The stress-responsive cytokine GDF-15 and sarcopenia: A systematic review and meta-analysis on aging muscle decline

    Mechanisms of ageing and development

  2. GDF-15 is associated with muscle mass in humans.

    “As in mice, serum levels of GDF-15 were correlated positively with age, but negatively with muscle mass in these subjects.”

    Humans

    Growth differentiation factor-15 as a biomarker for sarcopenia in aging humans and mice

    Experimental gerontology

  3. GDF-15 is associated with muscle mass in men only, after adjustment for age and number of drugs per day.

    “Elevated GDF15 concentrations were associated with lower measures of muscle mass, exclusively in men, after adjustment for age and number of drugs per day.”

    Humansin men only, after adjustment for age and number of drugs per dayskeletal musclemales

    Associations Between Serum GDF15 Concentrations, Muscle Mass, and Strength Show Sex-Specific Differences in Older Hospital Patients

    Rejuvenation research

  4. GDF-15 is associated with muscle mass in elderly women (ρ = -0.320, p < 0.01).

    “In contrast, GDF-15 correlated positively with age (ρ = 0.388, p < 0.001) and negatively with muscle mass (ρ = -0.320, p < 0.01).”

    Humansin elderly womenfemales

    Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women

    Experimental gerontology

  5. GDF-15 is associated with muscle mass in mice (strong negative correlation).

    “The serum levels of GDF-15 had a strong negative correlation with both muscle weight and exercise endurance capacity.”

    Animals

    Growth differentiation factor-15 as a biomarker for sarcopenia in aging humans and mice

    Experimental gerontology

Dementia

upin humans4

4 studies
  1. GDF-15 is associated with dementia in humans (proteins associated with earlier menopause).

    “proteins associated with earlier menopause, including GDF15, exhibited concordant associations with incident dementia risk and brain atrophy”

    Humansproteins associated with earlier menopausefemalesn = 15,012

    Plasma proteomics link menopause timing to brain aging and dementia risk

    Research squarePreprint

  2. GDF-15 is linked with a higher risk of dementia in humans (CHS participants; extreme quartiles; fully adjusted models).

    “analysis of extreme quartiles in fully adjusted models revealed a 3.5-fold higher risk of dementia (HR: 3.50 [1.97, 6.22])”

    HumansCHS participants; extreme quartiles; fully adjusted models

    Associations of Serum GDF-15 Levels with Physical Performance, Mobility Disability, Cognition, Cardiovascular Disease, and Mortality in Older Adults

    medRxiv : the preprint server for health sciencesPreprint

  3. GDF-15 is linked with a higher risk of dementia in sensitivity analyses (weighted median, MR-Egger or cis-SNP MR).

    “Sensitivity analyses showed higher GDF15 was significantly associated with higher dementia risk and worse cognitive function.”

    Humansin sensitivity analyses (weighted median, MR-Egger or cis-SNP MR)

    Exploring the possible causal effects of cardiac blood biomarkers in dementia and cognitive performance: a Mendelian randomization study

    GeroScience

  4. GDF-15 is associated with dementia in humans.

    “decline from cognitively normal status to mild cognitive impairment or dementia”

    Review

    Macrophage inhibitory cytokine-1/growth differentiation factor 15 as a marker of cognitive ageing and dementia

    Current opinion in psychiatry

More on Dementia

Cellular senescence

upin animals1upin human cells1upin humans1upin reviews1

4 studies
  1. GDF-15 is associated with cellular senescence in humans.

    “Among the SASP factors, GDF15 was expressed in the hepatocytes of patients with AH and was strongly associated with senescence markers.”

    Humanshepatocyte

    GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis

    JHEP reports : innovation in hepatology

  2. GDF-15 is associated with cellular senescence (peritumoral colonic epithelial cells).

    “we link GDF15 upregulation to senescence in peritumoral CECs”

    Animalsperitumoral colonic epithelial cellscolon

    Peritumoral colonic epithelial cell-derived GDF15 sustains colorectal cancer via regulation of glycolysis and histone lactylation

    Nature aging

  3. GDF-15 is associated with cellular senescence.

    “the GDF15 protein is a core factor secreted by senescent cells”

    Review

    GDF15/MIC-1: a stress-induced immunosuppressive factor which promotes the aging process

    Biogerontology

  4. GDF-15 is associated with cellular senescence in an islet preparation from a T1D donor.

    “elevated GDF15 secretion was associated with endogenous senescent beta cells in an islet preparation from a T1D donor”

    Cellsin an islet preparation from a T1D donorpancreatic islet

    Secreted GDF15 maintains transcriptional responses during DNA damage-mediated senescence in human beta cells

    American journal of physiology. Endocrinology and metabolism

More on Cellular senescence

Telomere length

downin humans4

4 studies
  1. GDF-15 is associated with telomere length in humans (Adjusted for age and sex).

    “shorter telomere length, diminished fluid intelligence, and reduced physical activity (all p < 0.001).”

    HumansAdjusted for age and sexn = 500,000

    Growth Differentiation Factor 15 Connects Stress and Ageing in a UK Biobank Cohort

    medRxivPreprint

  2. GDF-15 is associated with telomere length in humans after adjustment for confounding factors (β = -0.120, 95%CI [-0.197, -0.042]).

    “GDF15 was negatively associated with LTL (β = -0.120, 95%CI [-0.197, -0.042], p = 0.003)”

    Humansafter adjustment for confounding factorsleukocyte

    Serum Growth Differentiation Factor 15 is Negatively Associated with Leukocyte Telomere Length

    The journal of nutrition, health & aging

  3. GDF-15 is associated with telomere length in humans after adjustment for confounders, adjusted β = -0.200 (r = -0.434; adjusted β = -0.200 (95% CI -0.305 to -0.094)).

    “negatively correlated with telomere length (r = -0.434, p < 0.001)”

    Humansafter adjustment for confounders, adjusted β = -0.200PBMCmalesn = 120

    GDF15 as a biomarker of ageing

    Experimental gerontology

  4. GDF-15 is associated with telomere length in humans after adjusting for confounders (β-coefficient=-0.200).

    “telomere length (β-coefficient=-0.200, 95% CI -0.305 to -0.094, p<0.001)”

    Humansafter adjusting for confoundersmalesn = 120

    GDF-15 as a biomarker of aging

    Preprint

More on Telomere length

Obesity

upin humans3OR 3.28

3 studies
  1. GDF-15 predicts obesity in humans (controls versus obese groups) (AUC 0.939-0.954).

    “GDF-15 showed high discriminatory ability for controls versus obese groups (AUC 0.939-0.954)”

    Humanscontrols versus obese groupsn = 90

    Growth differentiation factor-15 and body roundness index in relation to cardiometabolic risk in young adults with obesity

    Endocrine

  2. GDF-15 is linked with a higher risk of obesity in humans (GDF-15 level above 618.4 pg/mL cut-off) (OR 3.28; 95% CI 1.48-7.27).

    “obesity (OR 3.28; 95% CI 1.48-7.27; p = 0.001)”

    HumansGDF-15 level above 618.4 pg/mL cut-offfemalesn = 146

    Associations Between Plasma Growth and Differentiation Factor-15 with Aging Phenotypes in Muscle, Adipose Tissue, and Bone

    Calcified tissue international

  3. Obesity is associated with GDF-15 in humans (obese (BMI ≥ 30 kg/m2) compared with overweight individuals).

    “higher in obese (BMI ≥ 30 kg/m2) compared to overweight (p = 0.002) individuals”

    Humansobese (BMI ≥ 30 kg/m2) compared with overweight individuals

    Growth differentiating factor-15 and adiposity in young adults: The African-PREDICT study

    International journal of obesity (2005)

More on Obesity

Body weight

downin humans1

1 study
  1. GDF-15 is associated with body weight in the metformin group (r = −0.67).

    “Changes in GDF-15 correlated inversely with changes in body weight in the metformin group (r = −0.67; P =.003), whereas no association was observed in the placebo group (r = 0.23; P =.359; and ).”

    Human trialin the metformin group96 weeksn = 17

    Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial

    Open forum infectious diseases

More on Body weight

HbA1c reduction

upin humans1

1 study
  1. GDF-15 is associated with HbA1c reduction in humans (univariate model; tertile 3 versus lowest tertile reference) (β 0.553, 95% CI 0.115 to 0.991).

    “Univariate linear regression analysis revealed a positive association between baseline GDF15 (tertile 3: β = 0.553, 95% CI 0.115 to 0.991, p = 0.014) and ΔHbA1c.”

    Human trialunivariate model; tertile 3 versus lowest tertile reference16 weeksn = 166

    Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial

    Biomedicines

More on HbA1c reduction

Cognitive composite score

downin humans1

1 study
  1. GDF-15 is associated with cognitive composite score in humans.

    “Higher levels of GDF15 and TNFR1 were associated with a worse trajectory in the cognitive composite score in adjusted models.”

    Human trial2 yearsn = 1,527

    Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study

    GeroScience

Event-related potential latency

upin humans1

1 study
  1. GDF-15 is associated with event-related potential latency in humans after IHHT (enhanced GDF15 expression) (R = 0.6263 (P330); R = 0.5715 (N200)).

    “The enhanced expression of GDF15 was also associated with longer latency of the event-related potentials P330 and N200”

    Human trialafter IHHT (enhanced GDF15 expression)

    Response of Circulating Inflammatory Markers to Intermittent Hypoxia-Hyperoxia Training in Healthy Elderly People and Patients with Mild Cognitive Impairment

    Life (Basel, Switzerland)

Montreal Cognitive Assessment score

downin humans1

1 study
  1. GDF-15 is associated with montreal Cognitive Assessment score in humans (before IHHT initiation) (R = −0.5799).

    “There was a negative correlation between MoCA score and the plasma GDF15 expression (R = −0.5799, p < 0.05) before the initiation of IHHT.”

    Human trialbefore IHHT initiation

    Response of Circulating Inflammatory Markers to Intermittent Hypoxia-Hyperoxia Training in Healthy Elderly People and Patients with Mild Cognitive Impairment

    Life (Basel, Switzerland)

All 264

Funding

7 grants since 2020

Japan Society for the Promotion of Science¥32MGouvernement du Canada | Canadian Institutes of Health ResearchCA$17.5KNatural Science Foundation of Hunan Province

Latest

Dec 2025: 25Jan 2026: 24Feb 2026: 23Mar 2026: 21Apr 2026: 13May 2026: 11Jun 2026: 21Jul 2026: 17Aug 2026: 15Sep 2026: 14Oct 2026: 32Nov 2026: 16232 papers in 12 months
Nature Metabolism

Blood protein model better predicts future diabetes risk

In about 20,000 UK Biobank participants, the model scored 0.86 for ranking diabetes risk, versus 0.74 for a blood-fat ratio.In about 20,000 UK Biobank participants, the model scored 0.86 for ranking diabetes risk, versus 0.74 for a blood-fat ratio.

Cohort · 20,612 peopleType 2 diabetes
AHA Scientific Sessions 2026 Abstract

Low blood pressure linked to higher cardiovascular risk

Compared with participants without hypotension, those diagnosed with low blood pressure had a heart failure hazard ratio of 1.69 over a median 16.8 years.Compared with participants without hypotension, those diagnosed with low blood pressure had a heart failure hazard ratio of 1.69 over a median 16.8 years.

Cohort · 475,447 peopleCardiovascular disease

See all 558 papers on GDF-15